Nathan L. Boyer, MD – Uniformed Services University of the Health Sciences DISCLOSURES March 04, 2022 The U.S. Food and Drug Administration (FDA) has approved the first-in-class biologic tezepelumab-ekko as an add-on maintenance treatment to standard therapy for severe asthma in adults and children aged 12 years and older. The approval is based on results...
Category: <span>Pharmaceutical Updates</span>
Post
New Era? ‘Double Selective’ Antibiotic Spares the Microbiome
A new antibiotic uses a never-before-seen mechanism to deliver a direct hit on tough-to-treat infections while leaving beneficial microbes alone. The strategy could lead to a new class of antibiotics that attack dangerous bacteria in a powerful new way, overcoming current drug resistance while sparing the gut microbiome. “The biggest takeaway is the double-selective component,”...
Post
Menopause, RSV, and More: 4 New Meds to Know
BOSTON — The US Food and Drug Administration (FDA) approved 55 new medications in 2023 and 11 more in 2024 to date. During a presentation on April 18 at the annual American College of Physicians Internal Medicine Meeting, Gerald Smetana, MD, professor of medicine in the Division of General Medicine at Beth Israel Deaconess Medical...
Post
DRUG MIMICS GOOD BACTERIA TO FIGHT NASTY GUT FUNGUS
JUNE 11TH, 2024POSTED BY NADINE YEHYA – UC DAVIS (Credit: Getty Images) TAGS CROHN’S DISEASEFUNGIGUT BACTERIAMEDICATIONSPROBIOTICSYEASTUNIVERSITY UNIVERSITY OF CALIFORNIA, DAVIS A common anti-inflammatory drug, mesalamine, can replace the work of good bacteria in fighting the nasty fungus Candida albicans in the gut. C. albicans, or candida, is known to cause yeast infections. In some cases,...
Post
Bempedoic Acid: A Statin-Intolerance Savior?
Perspective > Medscape Diabetes & Endocrinology > ADA 2023COMMENTARY Kevin Fernando, MBChB, MSc DISCLOSURES June 29, 2023 Cardiovascular disease remains one of the leading causes of death in patients with type 2 diabetes in the United Kingdom. Sadly, these patients are twice as likely to suffer or die from a cardiovascular event, compared with patients...
Post
Teprotumumab Gives Lasting Relief from Thyroid Eye Disease
Marilynn Larkin June 02, 2024 Nearly 2 years after their final infusion with the IGF-IR inhibitor teprotumumab (Tepezza), 82% of patients with thyroid eye disease did not need further treatment for their symptoms, revealed research presented today at ENDO 2024 and published in Thyroid. “Thyroid eye disease is a lifelong autoimmune disease that can worsen...
Post
Study reveals metformin’s role in slowing colorectal cancer cell growth
JUNE 11, 2024 by Flinders University Credit: Cancers (2024). DOI: 10.3390/cancers16112055 Flinders University researchers have analyzed how an antidiabetic treatment could help control the growth of tumors, potentially paving the way for the design of better cancer treatments. The new study investigated what happens when metformin, a type 2 diabetes medication, is used to treat...
Post
Researchers detect hidden ingredients and questionable claims in supplements
by Chapman University Credit: Pixabay/CC0 Public Domain A recent study published in Phytochemical Analysis, conducted by Schmid College of Science and Technology Professor Rosalee Hellberg and students Calin Harris, Diane Kim, Miranda Miranda and Chevon Jordan, reveals that some supplement companies may mislead customers with unproven health claims and undeclared ingredients. The researchers focused on...
Post
Strong trial results for Pfizer lung cancer drug
MAY 31, 2024 Credit: Unsplash/CC0 Public Domain A Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung cancer, results published Friday showed. Lorlatinib, which is already approved and available under the brand name Lobrena in the United States, was...
Post
Thyroid eye disease patients report maintained improvement two years after teprotumumab infusions
JUNE 2, 2024 by The Endocrine Society Credit: Pixabay/CC0 Public DomainMost patients with thyroid eye disease treated with teprotumumab didn’t require additional treatment nearly two years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, and published in the journal Thyroid. “Thyroid eye disease is a...